Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin
Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin
复制标题
DOI：
10.1038/srep18632
复制
发表时间：
2015-12-21
影响因子：
4.6
通讯作者：
de Hingh, I. H.
中科院分区：
文献类型：
--
作者：
van Oudheusden, T. R.;Razenberg, L. G.;de Hingh, I. H.
化疗和靶向治疗相结合可提高转移性结直肠癌 (mCRC) 患者的生存率。然而，这种姑息治疗对异时性腹膜癌病（PC）患者的结果仍然未知。目前基于人群的研究旨在调查姑息性全身治疗在结直肠起源的异时性 PC 患者中的使用和效果。 2010 年至 2011 年间，收集了 2003 年至 2008 年荷兰埃因霍温癌症登记处诊断为 M0 结直肠癌的所有患者的异时 PC 数据。收集并比较患者人口统计数据和化疗治疗的详细数据。 92 名异时性 PC 患者接受了姑息性化疗，相比之下，94 名患者未接受治疗。 36 名患者在治疗中添加了贝伐珠单抗 (39%)。不治疗、全身治疗和全身治疗+贝伐单抗的总生存期分别为3.4、13和20.3个月（P < 0.001）。男性是接受贝伐珠单抗的阳性预测因子，右侧原发肿瘤位置是阴性预测因子。大约 40% 的异时性 PC 患者除化疗外还接受贝伐单抗治疗。全身化疗联合贝伐珠单抗治疗可能会增加异时结直肠 PC 患者的生存率。
Combining chemotherapy and targeted therapies has resulted in an enhanced survival in metastatic colorectal cancer (mCRC) patients. However, the result of this palliative treatment in patients with metachronous peritoneal carcinomatosis (PC) remains unknown. The current population-based study aims to investigate the use and effect of palliative systemic treatment in patients with metachronous PC of colorectal origin. Data on metachronous PC were collected between 2010 and 2011 for all patients who were diagnosed with M0 colorectal cancer between 2003 and 2008 in the Dutch Eindhoven Cancer Registry. Patient demographics and detailed data on chemotherapeutic treatment were collected and compared. Ninety-two patients with metachronous PC received chemotherapy in a palliative setting compared to 94 patients without treatment. In 36 patients, Bevacizumab was added to the treatment (39%). Overall survival was 3.4, 13, and 20.3 months in the no treatment, systemic treatment and systemic treatment + Bevacizumab respectively (P < 0.001). Male gender was a positive predictor and right sided primary tumor location a negative predictor of receiving bevacizumab. Approximately 40% of patients with metachronous PC received bevacizumab in addition to chemotherapy. Treatment with systemic chemotherapy in combination with bevacizumab may increase survival in a patients with metachronous colorectal PC.